In IL-8 and Hs-CRP, inflammatory markers in colorectal cancer patients on chemotherapy, suggesting its potential as a complementary antitumor agent.

Reduction

Improvement
In the treatment outcomes of the patients with stroke by reducing the serum level of CRP, thus lowering the chances of developing ischemic attack and hemorrhagic stroke.